Featured News
GLP Toxicology for IND Studies
Integrating Non‑GLP and GLP Toxicology for Stronger IND Submissions
Contrary to popular belief, most development delays are a result of poor planning. Starting GLP studies too early or shifting from non‑GLP too late elevates costs, workload, and risk. Strong IND programs depend on GLP data, but success begins earlier. You need a clear link between non‑GLP insights and GLP study design from the start. When those pieces are disconnected, teams face avoidable signals, redesigns, and pressure on milestones.
Quick Decision Overview
- Use non‑GLP studies early to explore risk, refine dose selection, and de‑risk candidates.
- Use GLP toxicology studies when preparing regulatory submissions such as IND or CTA filings.
- Align both strategically to reduce delays and enhance the quality of your submission.
GLP versus Non‑GLP Toxicology: A Side‑by‑Side Comparison
Both study types generate valuable data. The difference lies in regulatory intent and documentation standards.
Why Non‑GLP Toxicology Matters Early
Non‑GLP studies provide the flexibility needed early in development, supporting dose‑range finding, organ identification, and rapid assessment of modality‑specific risks. They help refine study design before committing to the strict requirements of GLP.
Non‑GLP studies are typically used for:
- Dose‑range finding
- Target organ identification
- Early modality risk assessment
- Lead optimization
Because they are not bound by full Good Laboratory Practice documentation requirements, non‑GLP toxicology studies allow sponsors to explore safety signals quickly and refine study design before committing to larger GLP investments. Used strategically, non‑GLP toxicology reduces downstream surprises and strengthens the design of subsequent IND‑enabling studies.
Why You Should Incorporate Integrated Toxicology Studies
Early-stage non-GLP toxicology is designed to de-risk faster. Real-time safety data, integrated dose-range finding, and streamlined reporting help strengthen your transition to GLP toxicology and IND readiness.
Discover the benefits
Modern Considerations for Advanced Modalities
As drug development expands to biologics, cell and gene therapies, and complex small molecules, toxicology strategies must evolve alongside these innovations. GLP toxicology and non‑GLP studies must be designed with modality‑specific risk in mind.
Innovative approaches may include:
- New Approach Methodologies (NAMs)
- Digital pathology and advanced analytics
- Virtual control groups
- Real‑time data monitoring
These tools enhance predictive accuracy, strengthen data quality, and support responsible study design while maintaining regulatory compliance and IND readiness.